

Randomized double-blind trial.
Moderate-severe ulcerative colitis antiTNF naïve patients
randomised to: IFZ 5mg/kg, AZA 2.5mg/kg or a combination
IFZ+AZA

Primary outcome: steroid-free remission w16

Secondary outcomes: mucosal healing; Mayo score changes; FC changes

Results:

- Steroid-free w16: 39.7% combo vs 22.1% IFX vs 23.7% AZA; $p=0.017$, $p=0.03$
- Mucosal Healing w16: 62.8% combo vs 54.6% IFX vs 36.8% AZA; $p=ns$ / $=0.001$

Conclusions:

IFX+AZA combotherapy superior to IFX or AZA alone
achieving steroid free remission w16




Figure 2. Efficacy of AZA, IFX, or IFX/AZA combination treatment. (A) Patients achieving CS-free remission at week 16. (B) Patients with mucosal healing (Mayo endoscopy subscore of 0 or 1) at week 16. (C) Patients with partial Mayo score decrease of 1 or more at week 8. (D) Patients with partial Mayo score decrease of 2 or more at week 8. (E) Patients with total Mayo response at week 16. (F) Mean total Mayo score change from baseline at week 16.